科倫藥業(002422.SZ):擬籌劃推出股權激勵計劃事項
格隆匯11月22日丨科倫藥業(002422.SZ)公佈,公司為進一步建立、健全公司長效激勵機制、吸引和留住優秀人才,充分調動公司管理人員及核心骨幹的積極性,有效地將股東利益、公司利益和被激勵對象個人利益集合在一起,使各方共同關注公司的長遠發展,根據規定,擬籌劃推出股權激勵計劃事項。
經初步研究,此次激勵計劃擬授予激勵對象權益總計不超過496萬股,涉及的標的股票種類為人民幣A股普通股,佔公司目前股本總額不超過0.3480%。
公司全部有效期內股權激勵計劃所涉及的標的股票總數不超過公司股本總額的10%。激勵計劃中任何一名激勵對象通過全部有效期內的股權激勵計劃獲授的公司股票數量不超過公司股本總額的 1%。本次股權激勵計劃的具體激勵規模,待公司討論確定後,在後續的激勵計劃草案中予以明確。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.